- Home
- USCB vs GOSS Comparison
USCB vs GOSS Comparison
Compare USCB & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USCB
- GOSS
- Stock Information
- Founded
- USCB 2002
- GOSS 2015
- Country
- USCB United States
- GOSS United States
- Employees
- USCB N/A
- GOSS N/A
- Industry
- USCB Major Banks
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- USCB Finance
- GOSS Health Care
- Exchange
- USCB Nasdaq
- GOSS Nasdaq
- Market Cap
- USCB 316.4M
- GOSS 262.5M
- IPO Year
- USCB 2021
- GOSS 2019
- Fundamental
- Price
- USCB $17.00
- GOSS $1.25
- Analyst Decision
- USCB Buy
- GOSS Strong Buy
- Analyst Count
- USCB 3
- GOSS 3
- Target Price
- USCB $20.50
- GOSS $7.33
- AVG Volume (30 Days)
- USCB 27.3K
- GOSS 2.6M
- Earning Date
- USCB 07-24-2025
- GOSS 08-11-2025
- Dividend Yield
- USCB 2.35%
- GOSS N/A
- EPS Growth
- USCB 78.48
- GOSS N/A
- EPS
- USCB 1.39
- GOSS N/A
- Revenue
- USCB $84,457,000.00
- GOSS $124,590,000.00
- Revenue This Year
- USCB $23.28
- GOSS N/A
- Revenue Next Year
- USCB $7.02
- GOSS $91.14
- P/E Ratio
- USCB $12.23
- GOSS N/A
- Revenue Growth
- USCB 34.16
- GOSS N/A
- 52 Week Low
- USCB $11.88
- GOSS $0.66
- 52 Week High
- USCB $21.86
- GOSS $1.55
- Technical
- Relative Strength Index (RSI)
- USCB 59.44
- GOSS 49.48
- Support Level
- USCB $16.08
- GOSS $1.20
- Resistance Level
- USCB $17.80
- GOSS $1.33
- Average True Range (ATR)
- USCB 0.48
- GOSS 0.10
- MACD
- USCB 0.13
- GOSS -0.02
- Stochastic Oscillator
- USCB 64.09
- GOSS 18.37
About USCB USCB Financial Holdings Inc.
USCB Financial Holdings Inc is a community bank. Through its network of branches and its online banking platform, it offers customers a wide range of financial products and services such as Personal and Business Checking, Savings, Credit Cards, and Real Estate Loans.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.